CTKB
Cytek Biosciences, Inc.
$4.01
Stable Earnings Power
40%
P/Adj-EPS × Normalized Multiple
Strong
·
Conviction
Overvalued
Trading 170.6% above fair value
You pay
$4.01
Bear
$1.17
Fair
$1.48
Bull
$1.77
Bear
$1.17
-70.8%
$0.03 × 18x P/E
Fair
$1.48
-63.0%
$0.03 × 22x P/E
Bull
$1.77
-55.9%
$0.03 × 27x P/E
Key Value Driver
Normalized P/E multiple (22x base case)
Implied Market Multiple
158.7x
Summary
Our base-case estimate uses a valuation based on adjusted earnings per share and a normalized price-to-earnings multiple. We then blend that result with the average analyst price target of $5.13 from 5 analysts, using a 20% weight on analyst consensus. That produces an estimated intrinsic value of $1.48 per share.
Warnings
Wall Street's average price target is $5.13 (from 5 analysts). Our estimate is 89% below the consensus -- consider that gap carefully.
Key Risks
- Growth DCF inappropriate — terminal value assumptions dominate
- EV/EBITDA misleading for regulated businesses where capex is mandated
- Regulatory risk is a fat tail not visible in normal multiples